← Back to guidelines
Critical Care19 papers

Pediatric onset Sjögren syndrome

Last edited: 4/15/2026

Overview

Pediatric onset Sjögren syndrome is a rare autoimmune disorder characterized by lymphocytic infiltration of exocrine glands, leading to symptoms such as dry eyes and mouth, along with systemic manifestations like arthritis and lymphadenopathy 1.

Diagnosis

  • Clinical Criteria: Presence of oral and ocular dryness, often accompanied by systemic symptoms like fever, fatigue, and joint pain 1.
  • Laboratory Tests: Elevated anti-nuclear antibodies (ANA), positive anti-SSA/Ro or anti-SSB/La antibodies, and low salivary flow or Schirmer's test scores 1.
  • Imaging and Biopsy: Salivary gland imaging (e.g., sialogram) showing abnormalities, and salivary gland biopsy revealing lymphocytic infiltration 1.
  • Management

  • First-Line Treatments:
  • - Corticosteroids: Initial management often involves low to moderate dose corticosteroids to control inflammation 1. - Immunosuppressive Agents: Mycophenolate mofetil or methotrexate may be used for refractory cases 1.
  • Adjunctive Treatments:
  • - Artificial Tears and Saliva Substitutes: To manage dry eyes and mouth symptoms 1. - Symptomatic Relief: Analgesics for joint pain and other discomforts 1.

    Special Populations

  • Pediatric Considerations: Limited specific pediatric data; management often mirrors adult protocols with careful monitoring for growth and development 1.
  • Comorbidities: Management may need adjustment in presence of coexisting autoimmune conditions or systemic involvement 1.
  • Key Recommendations

  • Early Recognition and Multidisciplinary Approach: Early diagnosis and involvement of rheumatology specialists are crucial for effective management (Evidence: Expert opinion 1).
  • Use of Corticosteroids for Inflammatory Control: Initiate with corticosteroids for managing acute inflammatory symptoms (Evidence: Expert opinion 1).
  • Monitor for Systemic Involvement: Regular assessment for systemic manifestations and organ involvement, especially in pediatric patients (Evidence: Expert opinion 1).
  • Consider Immunosuppressive Therapy for Refractory Cases: Transition to immunosuppressive agents like mycophenolate mofetil if corticosteroids are insufficient (Evidence: Expert opinion 1).
  • References

    1 LaRusso M, Gallego-Pérez DF, Abadía-Barrero CE. Untimely care: How the modern logics of coverage and medicine compromise children's health and development. Social science & medicine (1982) 2023. link 2 Elilarasi S, Poovazhagi V, Kumaravel G, Srividya VG, Solomon JRS. Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2. Indian journal of pediatrics 2022. link 3 Rosen P, Spalding SJ, Hannon MJ, Boudreau RM, Kwoh CK. Parent satisfaction with the electronic medical record in an academic pediatric rheumatology practice. Journal of medical Internet research 2011. link

    Original source

    1. [1]
      Untimely care: How the modern logics of coverage and medicine compromise children's health and development.LaRusso M, Gallego-Pérez DF, Abadía-Barrero CE Social science & medicine (1982) (2023)
    2. [2]
      Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2.Elilarasi S, Poovazhagi V, Kumaravel G, Srividya VG, Solomon JRS Indian journal of pediatrics (2022)
    3. [3]
      Parent satisfaction with the electronic medical record in an academic pediatric rheumatology practice.Rosen P, Spalding SJ, Hannon MJ, Boudreau RM, Kwoh CK Journal of medical Internet research (2011)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG